par John R. Fischer
, Senior Reporter | January 14, 2020
"Colorectal and lower gastrointestinal procedures are the fastest-growing procedures in the United States," he said. "Despite significant technological advancements and improved patient outcomes that can reduce the total cost of care, adoption of minimally-invasive colon resection has been limited even though rates of these conditions are growing. There is a significant opportunity to increase the adoption of minimally-invasive procedures for these patients by advancing the next generation of robot-assisted surgeries — and thereby offering reduced recovery time, pain, blood loss, and overall complications."
The company has begun to develop a family of procedure-specific mini-robots for other operations including hernia repair and gallbladder removal.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
MIRA consists of more than 200 patents and applications.
The Series B+ financing was led by returning investor Bluestem Capital, with participation from returning investor PrairieGold Venture Partners, as well as from Genesis Innovation Group and other affiliated investors. The funds raised will support regulatory and clinical programs that will help pave the way for commercialization of MIRA.
The study will take place at a number of U.S. investigational sites.Back to HCB News